Meta-Analysis
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 16, 2024; 12(2): 335-345
Published online Jan 16, 2024. doi: 10.12998/wjcc.v12.i2.335
Efficacy and safety of Yangxue Qingnao Granules in treatment of migraine: A systematic review and meta-analysis
Bo Zhou, Gui-Shu Wang, Yu-Ning Yao, Tong Hao, Huan-Qin Li, Ke-Gang Cao
Bo Zhou, Department of Neurology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
Gui-Shu Wang, Department of Infectious Disease, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China
Yu-Ning Yao, Tong Hao, Ke-Gang Cao, Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing 100700, China
Huan-Qin Li, Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100010, China
Author contributions: Zhou B and Cao KG designed the study, conducted the analysis, and drafted the manuscript; Wang GS and Yao YN performed the literature selection; Li HQ and Cao KG did the quality assessment; Fan HH and Hao T performed the data extraction; Zhou B and Wang GS did part of the statistical work; Cao KG and Li HQ critically revised the manuscript.
Conflict-of-interest statement: All the authors have no conflict of interest related to the manuscript.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ke-Gang Cao, MD, Chief Physician, Institute for Brain Disorders, Beijing University of Chinese Medicine, No. 5 Dongzhimen, Dongcheng District, Beijing 100700, China. kgdoctor@sina.com
Received: October 26, 2023
Peer-review started: October 26, 2023
First decision: November 8, 2023
Revised: November 22, 2023
Accepted: December 21, 2023
Article in press: December 21, 2023
Published online: January 16, 2024
Processing time: 77 Days and 2.1 Hours
Core Tip

Core Tip: Traditional Chinese medicine is widely used as a treatment option for migraine. Clinical studies have confirmed the effectiveness of Yangxue Qingnao Granules (YXQN) for treatment of migraine. However, there is still insufficient evidence to evaluate the efficacy of YXQN for migraine. Therefore, this meta-analysis aimed to systematically integrate clinical trials to evaluate the efficacy and safety of YXQN alone in the treatment of migraine and provide a basis for its further clinical application and research.